ARMOR Study

ALSARMOR.COM



ARMOR Study:

Take part in an investigational gene therapy trial for people living with ALS.



Learn More

ARMOR is now open and recruiting.
For eligibility requirements, study locations and contact details, see **ALSARMOR.COM**

ARMOR Study



ARMOR is a Phase 1 trial being conducted to learn more about an investigational study drug called INS1202, as a potential treatment for ALS.

The main goal of this study is to find the right dose of investigational compound INS1202 and evaluate if it is safe and tolerable when given as a single injection into the spinal fluid. We are looking at how the investigational compound INS1202 works in the body. This study is for people aged 18 to 79 who have ALS, a disease affecting nerve cells, and either have a specific genetic change called SOD1 mutation or do not have any known genetic changes related to ALS.

How will INS1202 be given?

- ARMOR is a first-in-human investigational research study designed to assess the safety of INS1202*.
- INS1202 is given as a one-time intrathecal (IT). This means that the medication is delivered directly into the fluid-filled space around the spinal cord.
- The potential effect of INS1202 will be assessed using a biomarker for nerve damage and physical function tests.
- The study will last around a year, with an additional follow-up period of four years.

*INS1202 has not been approved for use for any indication in any country.

How do I know if I can take part in the study?

Eligibility information*

1 Age
18 to 79 years of age (both inclusive).

2 ALS Diagnosis
Diagnosed with amyotrophic lateral sclerosis (ALS) with or without SOD1 mutations.

3 Disease duration
Symptomatic ALS with disease duration less than or equal to 42 months.

4 Able to swallow pills
Corticosteroids will be dispensed and taken daily for approximately 8 weeks and eventually tapered off.

5 Sporadic ALS
Negative testing for known mutations associated with familial ALS

OR

6 SOD1-ALS
SOD1 mutation with no other genetic mutations associated with familial ALS

*Other eligibility criteria may apply.



Learn More

To learn more about the ARMOR study, please contact Insmed Medical Information. For full details of the study, see **ALSARMOR.COM**

Insmed®

© 2026 Insmed Incorporated. All rights reserved.
Insmed and the Insmed logo are registered trademarks of Insmed.
ARMOR and the associated logo are trademarks of Insmed Incorporated
MED-US-ALS-00007 09/26